Brokers Set Expectations for Catalyst Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $0.67 per share for the quarter, up from their prior estimate of $0.64. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.69 EPS, Q3 2025 earnings at $0.67 EPS and FY2025 earnings at $2.70 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%.

CPRX has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. Finally, Citigroup began coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.43.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX traded up $0.10 during mid-day trading on Friday, hitting $14.78. The company’s stock had a trading volume of 60,852 shares, compared to its average volume of 1,458,409. Catalyst Pharmaceuticals has a 1 year low of $11.09 and a 1 year high of $17.76. The business’s fifty day moving average is $15.52 and its two-hundred day moving average is $14.61. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 0.83 and a beta of 0.89.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the transaction, the insider now directly owns 124,433 shares in the company, valued at approximately $2,045,678.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 819 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in Catalyst Pharmaceuticals by 4.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 1,290 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Catalyst Pharmaceuticals by 5.3% during the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 1,456 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 15.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 1,719 shares during the period. Finally, Cerity Partners LLC boosted its position in Catalyst Pharmaceuticals by 11.5% during the 4th quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 1,780 shares during the period. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.